American heart journal plus : cardiology research and practice最新文献

{"title":"Prognostic impact of cardiac dysfunctions in patients with ST-segment elevation myocardial infarction","authors":"Yan Zhou ,&nbsp;Jasmine Melissa Marquard ,&nbsp;Lars Nepper Christensen ,&nbsp;Kiril Aleksov Ahtarovski ,&nbsp;Kasper Kyhl ,&nbsp;Christoffer Göransson ,&nbsp;Lars Køber ,&nbsp;Lene Holmvang ,&nbsp;Frants Pedersen ,&nbsp;Henning Kelbæk ,&nbsp;Niels Vejlstrup ,&nbsp;Jacob Thomsen Lønborg ,&nbsp;Thomas Engstrøm","doi":"10.1016/j.ahjo.2025.100628","DOIUrl":"10.1016/j.ahjo.2025.100628","url":null,"abstract":"<div><h3>Background</h3><div>The incidence and impact of cardiac dysfunctions after ST-segment elevation myocardial infarction (STEMI) are not understood. We aimed to characterize the prevalence of follow-up systolic and diastolic dysfunction and their associations with long-term outcomes after STEMI.</div></div><div><h3>Methods and results</h3><div>This sub-study of the DANAMI-3 trial included 542 patients with STEMI. Cardiac magnetic resonance (CMR)-defined systolic/diastolic impairment was applied to define systolic/diastolic dysfunction. Systolic dysfunction was defined as left ventricular ejection fraction (LVEF) &lt; 50 %, and diastolic dysfunction as peak filling rate/end-diastolic volume (PFR/EDV) ≤ 2.55 by CMR three months after STEMI. The primary outcome was a composite of all-cause mortality and hospitalization for heart failure. Secondary outcomes were individual components of the primary outcome. During a median follow-up of 10.5 years, 103 patients died or were hospitalized for heart failure. A total of 101 and 232 patients had systolic and diastolic dysfunction at three months. Cox regression showed that LVEF was significantly associated with the outcomes, while PFR/EDV was not associated with any outcome. Systolic dysfunction (LVEF&lt;50 %) was associated with the primary endpoint (adjusted hazards ratio [HR] 2.73), all-cause mortality (aHR 2.26), and hospitalization for heart failure (aHR 7.87). The incidences of isolated diastolic dysfunction, isolated systolic dysfunction and both cardiac dysfunctions were 150, 19 and 82. Patients with isolated systolic dysfunction and both dysfunctions were associated with the outcomes.</div></div><div><h3>Conclusions</h3><div>Cardiac dysfunctions derived from CMR-defined systolic/diastolic impairment showed in about half of the three-month STEMI-survivors. Systolic dysfunction regardless of diastolic dysfunction is a significant predictor of long-term outcomes after STEMI.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100628"},"PeriodicalIF":1.8,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mendelian randomization of autoimmune hepatitis and cardiovascular diseases","authors":"Feng Tang ,&nbsp;Tian Jun Zhao ,&nbsp;Pei Wen Dong ,&nbsp;Kai Di Sun ,&nbsp;Xiao Bin Sun ,&nbsp;Qiong Wang","doi":"10.1016/j.ahjo.2025.100627","DOIUrl":"10.1016/j.ahjo.2025.100627","url":null,"abstract":"<div><div>Previous studies have shown that autoimmune hepatitis (AIH) is associated with cardiovascular diseases (CVD), but the potential causal relationship between genetic susceptibility to AIH and CVD risk is unknown. This study systematically investigated the potential association between genetically determined AIH and the risk of CVD. The analysis was conducted by genome-wide association studies (GWAS), considering AIH as the exposure and cardiovascular disease as the endpoint. Mendelian randomization (MR) analysis was performed using inverse variance weighting (IVW) as the primary method. Additionally, a series of pleiotropy, heterogeneity test and sensitivity analyses were conducted to verify the reliability of the results.MR analysis showed that genetic susceptibility to AIH was associated with a higher risk of atrial fibrillation [OR = 1.01, 95 % CI (1.00–1.02), <em>p</em> = 0.025]. However, it was found that negative relationship with dilated cardiomyopathy [OR = 0.91, 95 %CI (0.87–0.95), <em>p</em> &lt; 0.001], coronary heart disease [OR = 0.94, 95 %CI (0.91–0.96), p &lt; 0.001], hypertension [OR = 0.97, 95 % CI (0.96–0.99), p &lt; 0.001], ischemic stroke [OR = 0.97, 95 % CI (0.96–0.99), <em>p</em> = 0.009], and intracerebral hemorrhage [OR = 0.95, 95 % CI (0.91–0.99), <em>p</em> = 0.013]. Sensitivity analysis has shown no evidence of horizontal pleiotropy or heterogeneity. Although some ORs are statistically significant, their clinical significance may be limited. In conclusion, our MR study explored the causal role of AIH in the etiology of CVD, which would help improve our understanding of the basic disease mechanisms of AIH and provide comprehensive CVD assessment and treatment for AIH patients.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100627"},"PeriodicalIF":1.8,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of carperitide on mortality and ANP levels in acute heart failure: A systematic review and meta-analysis","authors":"Allahdad Khan ,&nbsp;Shree Rath ,&nbsp;Saad Ahmed Waqas ,&nbsp;Umama Alam ,&nbsp;Muhammad Abdullah Ali ,&nbsp;Shaista Khadim ,&nbsp;Usman Ali Akbar ,&nbsp;Muhammad Aamir Laghari ,&nbsp;Peter Collins ,&nbsp;Raheel Ahmed","doi":"10.1016/j.ahjo.2025.100624","DOIUrl":"10.1016/j.ahjo.2025.100624","url":null,"abstract":"<div><h3>Background</h3><div>Acute heart failure (AHF) is a common and severe condition associated with high morbidity and mortality. Carperitide, a recombinant human atrial natriuretic peptide, has been widely used in Japan for managing AHF. However, its effectiveness in improving clinical outcomes such as mortality rates remains unclear, with conflicting evidence from studies.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted on studies comparing carperitide with placebo in AHF patients. Six studies including randomized and observational studies involving 30,665 patients were included, with primary outcomes being in-hospital mortality, heart failure-related mortality, and atrial natriuretic peptide (ANP) levels at 24 h. Statistical analysis was performed using the Mantel-Haenszel method for dichotomous outcomes and inverse variance for continuous outcomes.</div></div><div><h3>Results</h3><div>The meta-analysis found no significant difference in heart failure-related mortality (RR: 0.81; 95 % CI: 0.45–1.45) between carperitide and placebo groups. Following resolution of heterogeneity, a significantly higher in-hospital mortality was found in the carperitide group compared to placebo (RR: 1.16, 95 % CI: 1.07 to 1.27). However, ANP levels were significantly higher in the carperitide group (MD: 10.60; 95 % CI: 4.58–16.61) at 24 h.</div></div><div><h3>Conclusion</h3><div>Carperitide increases ANP levels in patients with acute heart failure but does not reduce heart failure related mortality and is associated with higher in-hospital mortality. These findings suggest that its clinical benefits are limited, and safety concerns remain. Further high-quality trials are needed to better define its role, optimal patient selection, and long-term outcomes.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100624"},"PeriodicalIF":1.8,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose optimization and utilization trends of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction in Ethiopia","authors":"Minimize Hassen ,&nbsp;Birhane Tilahun Worku ,&nbsp;Tewodros Solomon ,&nbsp;Mulat Belete Demessie ,&nbsp;Teklehaimanot Fentie Wendie ,&nbsp;Oumer Sada Muhammed ,&nbsp;Mengistie Yirsaw Gobezie","doi":"10.1016/j.ahjo.2025.100623","DOIUrl":"10.1016/j.ahjo.2025.100623","url":null,"abstract":"<div><h3>Background</h3><div>Nascent evidence-based guidelines advocate the use of Mineralocorticoid Receptor Antagonists (MRAs) in all heart failure patients with reduced ejection fraction (HFrEF) to abridge cardiovascular mortality and morbidity. This study assessed the utilization patterns and dose optimization of MRAs among patients with HFrEF at Dessie Comprehensive Specialized Hospital, Ethiopia, from March to August 2024.</div></div><div><h3>Methods</h3><div>A cross-sectional analysis of 260 adult patients with confirmed HFrEF, who had been under follow-up for at least six months, was conducted. MRA use and dose optimization were evaluated according to 2022 American Heart Association (AHA) guidelines. Logistic regression identified factors associated with MRA use, with statistical significance set at <em>p</em> &lt; 0.05.</div></div><div><h3>Results</h3><div>Among the 260 patients, 168 (64.6 %) were prescribed MRA, all receiving spironolactone. Of these, 119 (69.1 %) used it to reduce cardiovascular mortality, while 30.9 % used it for its potassium-sparing effect. However, only 38 (22.6 %) patients received the optimal dose, with a mean daily dose of 22.3 mg. MRAs underuse was observed in 83 (31.9 %) patients. Factors positively associated with MRA use included female sex (AOR = 2.79, 95 % CI: 1.33–5.85), NYHA class III (AOR = 4.99, 95 % CI: 1.71–14.61), diuretic use (AOR = 7.58, 95 % CI: 3.02–19.05), and taking five or more medications (AOR = 3.87, 95 % CI: 1.46–10.29). Conversely, negative associations were found with secondary prevention agents (AOR = 0.04, 95 % CI: 0.01–0.22) and a baseline serum potassium level of 5–5.5 meq/L (AOR = 0.20, 95 % CI: 0.08–0.53).</div></div><div><h3>Conclusion</h3><div>While MRA use is common, optimal dosing remains suboptimal. Clinicians should adhere to guideline recommendations to ensure optimal dosing and maximize clinical benefits.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100623"},"PeriodicalIF":1.8,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical function decline due to rehospitalization in older patients with heart failure and its contributing factors","authors":"Takahiro Shimoda ,&nbsp;Shinzi Suzuki ,&nbsp;Daisuke Mizukoshi ,&nbsp;Tomoko Terai","doi":"10.1016/j.ahjo.2025.100622","DOIUrl":"10.1016/j.ahjo.2025.100622","url":null,"abstract":"<div><h3>Background</h3><div>Older patients with heart failure often experience decreased physical activity, which reduces their ability to perform activities of daily living. Additionally, this physical function decline is exacerbated with each rehospitalization. However, the extent of this decline with rehospitalization in older patients with heart failure remains unclear, as do the characteristics of this patient group. Therefore, this study aimed to investigate the extent of physical function decline due to rehospitalization in older patients with heart failure and identify the factors associated with it.</div></div><div><h3>Methods</h3><div>Patients with heart failure aged ≥65 years who were hospitalized twice between September 2019 and June 2022 were enrolled. Patients were evaluated using the Short Physical Performance Battery (SPPB) at each admission and discharge. Analysis of variance was used to examine the impact of rehospitalization on physical function.</div></div><div><h3>Results</h3><div>Fifty-seven patients were evaluated in this study. SPPB scores were significantly lower at the second discharge than at the first discharge (<em>P</em> = 0.009). Overall, the SPPB score at the second discharge was 92 % (67–100 %) of that at the first discharge. Furthermore, patients with decreased SPPB scores at the second discharge, compared to those at the first discharge, had significantly lower SPPB scores at the second admission than those who maintained their scores.</div></div><div><h3>Conclusions</h3><div>Older patients with heart failure experienced a 10 % decline in physical function due to rehospitalization. Moreover, those with decreased physical function at the second discharge had already exhibited reduced physical function at the time of the second admission.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100622"},"PeriodicalIF":1.8,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of postoperative atrial fibrillation (POAF) on outcomes after coronary artery bypass grafting: A meta-analysis of unique 247,270 patients from 50 studies","authors":"Ahmed K. Awad ,&nbsp;Mohammed A. Elbahloul ,&nbsp;Omar Al-omoush ,&nbsp;Omar Abdelnasser ,&nbsp;Momen Hajali ,&nbsp;Ahmed Abdelnasser ,&nbsp;Othman Saleh ,&nbsp;Abdalrahman Altiti ,&nbsp;Haytham Elgharably ,&nbsp;Mohammad El Diasty","doi":"10.1016/j.ahjo.2025.100621","DOIUrl":"10.1016/j.ahjo.2025.100621","url":null,"abstract":"<div><h3>Background</h3><div>Postoperative atrial fibrillation (POAF) can occur in up to 53.1 % of patients undergoing cardiac surgery. This serious condition has been associated with increased risk of morbidity and mortality during the initial weeks after the procedure. In this updated meta-analysis, we aim to study the impact of POAF on outcomes in patients undergoing CABG surgery.</div></div><div><h3>Methods</h3><div>We searched PubMed, Scopus, Cochrane Library, and WOS from inception till April 15, 2024. The pooled effect sizes were mean difference (MD) for continuous outcomes and odds ratio (OR) for dichotomous outcomes and a 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>A total of 247,270 patients from 50 studies were included. Mean age ranged between 56.5 and 76 years and mean follow-up time duration ranged from six months to 15 years. In-hospital, 30-days, and long-term mortality were significantly higher in patients with POAF compared to patients without POAF with (OR: 2.37; 95 % CI: 1.45–3.87; <em>P</em> = 0.0033), (OR: 2.33; 95 % CI: 1.74–3.13; <em>P</em> &lt; 0.01), and (OR: 2.15; 95 % CI: 1.8–2.54; <em>P</em> &lt; 0.01respectively. In terms of stroke, both short- and long-term strokes were significantly higher in patients with POAF with (OR: 2.54; 95 % CI: 2.05–3.15; P &lt; 0.01) and (OR: 1.92; 95 % CI: 1.37–2.68; <em>P</em> &lt; 0.0007), respectively. Although POAF has significant longer hospital and intensive care unit stay and higher risk for post-operative renal failure and myocardial infarction, there was no significant difference in revascularization and reintubation rates in patients with POAF with (OR: 1.11; 95 % CI: 0.48–2.54; <em>P</em> = 0.656) and (OR: 2.72; 95 % CI: 0.86–8.67; <em>P</em> = 0.0742), respectively. The need for intra-aortic balloon pump was higher in POAF group with (OR: 1.84; 95 % CI: 1.42–2.37; <em>P</em> &lt; 0.01) as well as the risk of developing heart failure with OR: 1.8; 95 % CI: 1.43–2.26; <em>P</em> = 0.0012.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that POAF group may be associated with higher short-term mortality, long-term mortality, and length of hospital and ICU stay in patients undergoing CABG. Furthermore, there was a higher association between POAF and some postoperative complications such as stroke, acute renal failure, acute heart failure, and pneumonia. However, POAF did not seem to significantly affect rates of acute MI and reintubation.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100621"},"PeriodicalIF":1.8,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review on the effects of fasting on cardiac patients","authors":"Alaaeddine El Ghazawi ,&nbsp;Dunia Alhareth ,&nbsp;Marwan Refaat","doi":"10.1016/j.ahjo.2025.100620","DOIUrl":"10.1016/j.ahjo.2025.100620","url":null,"abstract":"<div><div>Fasting in Ramadan involves the cessation of food, water, and other behaviors from dawn to sunset, creating a unique physiological stressor that might have a potentially injurious or beneficial effect on cardiac patients. Its impact should be known so as to optimize patient care. The aim of this paper is to review the literature relating to the effects of Ramadan fasting on cardiac health, with particular regard to high-risk patient management, medication adherence, and life-style modifications. Available data suggests that fasting in Ramadan is safe for stable cardiac patients, with improvements in BMI, lipid profiles, blood pressure, and others. However, high-risk groups, including patients with recent myocardial infarction or severe heart failure, were considered inappropriate for fasting. Additionally, medication adjustments and lifestyle changes regarding balanced diets and hydration strategies are necessary to make fasting safe in cardiac patients who are candidate for fasting patients. These findings support the need for future tailored fasting plans and evidence-based guidelines to optimize outcomes in cardiac patients.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100620"},"PeriodicalIF":1.8,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and differences in cardiovascular disease and alzheimer's disease-related mortality among older adults in the United States, 1999 to 2023: A CDC WONDER database analysis","authors":"Jianren Wen ,&nbsp;Jingxuan Hu ,&nbsp;Guohui Zou","doi":"10.1016/j.ahjo.2025.100618","DOIUrl":"10.1016/j.ahjo.2025.100618","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) and Alzheimer's disease (AD) are leading causes of death in the United States and often co-occur, worsening outcomes. AD contributes to CVD mortality through shared risk factors, neurovascular dysfunction, and secondary complications such as immobility and dysautonomia. As global aging intensifies, mortality trends and disparities between these diseases remain poorly summarized. This study examines CVD- and AD-related mortality trends from 1999 to 2023 among U.S. adults aged 65 and older, by sex, race, and region.</div></div><div><h3>Methods</h3><div>The death certificates of individuals aged 65 years &gt; from 1999 to 2023 were extracted using the CDC WONDER multi-cause database and listed I00–I99 (CVD) and G30 (AD) as the criteria. Age-adjusted mortality rate per 100,000 people (AAMR) was calculated and Joinpoint regression was used to estimate mean annual percentage change (AAPC) and annual percentage change (APC).</div></div><div><h3>Results</h3><div><strong>A</strong> total of 1,283,881 deaths from CVD combined with AD were recorded from 1999 to 2023. The overall AAMR increased from 110.13 (95 % CI: 109.02 to 111.25) in 1999 to 116.80 (95 % CI: 115.87 to 117.74) in 2023 (APC: 0.14 (95 % CI: −1.00 to 1.29)). AAMR is consistently higher for women than for men (2023: 126.95 vs 100.64). By race, non-Hispanic whites had the highest number of deaths in 2023 (121.46 (95 %CI: 120.37 to 122.55)), followed by blacks (110.50 ((95 %CI: 107.35 to 113.65), Hispanic ((95 %CI: 112.97 (109.84 to 116.10)) and other races ((95 %CI:74.05 (71.20 to 76.91)). The regional distribution showed that the AAMR in the West was the highest in 2023 (158.43 (95 % CI: 156.13 to 160.74)), followed by the Midwest (118.32 (95 %CI: 116.28). to 120.36)), the South (113.36 (95 %CI: 111.85 to 114.87)) and the Northeast (73.15 (95 %CI: 71.47 to 74.84)). AAMR is highest in people over 85 years of age (17.6). Between 1999 and 2023, the AAMR in rural areas (36.90) was higher than in urban areas (28.75).</div></div><div><h3>Conclusion</h3><div>The age-adjusted mortality rate of CVD combined with AD in the United States continued to increase from 1999 to 2023, with the highest burden among women, non-Hispanic whites, rural areas, and individuals over 85 years of age. The results suggest the need for targeted early interventions to mitigate disparities and reduce mortality from comorbidities.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100618"},"PeriodicalIF":1.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary predictors of heart failure with preserved ejection fraction among middle-aged adults in the CARDIA study","authors":"Meaghan Osborne ,&nbsp;Charlotte Turner ,&nbsp;Shaun Cardozo ,&nbsp;Dragana Komnenov","doi":"10.1016/j.ahjo.2025.100619","DOIUrl":"10.1016/j.ahjo.2025.100619","url":null,"abstract":"<div><div>Heart failure (HF) is among the leading diagnoses for those admitted to the hospital over 65 years old in high-income countries. While there is strong evidence for the use of pharmacological interventions in the treatment of HF with reduced ejection fraction (HFrEF), there is limited evidence for a similar approach to decreasing morbidity and mortality of HF with preserved ejection fraction (HFpEF). This discrepancy highlights the importance of lifestyle change (i.e. diet) for prevention of HFpEF. Given the paucity of data on dietary predictors of HFpEF and the recent changes in diagnostic criteria, we set out to assess the associations of dietary and demographic predictors with HFpEF in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. We found that males in their fifties compared to age-matched females had worse measures of diastolic function (e’ lateral: 8.47 ± 2.28 vs. 8.98 ± 2.49, <em>p</em> &lt; .001) and myocardial shortening (i.e. GLS: −15.91 ± 2.73 vs −16.98 ± 3.1, <em>p</em> &lt; .001). Each one point of GLS increase was associated with 12 % increase in risk of HFpEF, while HDL intake was found to be protective against HFpEF. We also found that higher dietary HDL intake when individuals were in their fifties was associated with higher (i.e. better) measures of both e’ lateral and e’ septal velocities. Our data indicate that GLS appears to be a robust predictor of HFpEF and is influenced by dietary behaviors across the lifespan that affect BMI in males and hypertension in females.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100619"},"PeriodicalIF":1.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the potential of the outcome-oriented nursing assessment for acute care (ePA–AC) to identify cardiovascular patients at risk for unplanned 30- and 180-day all-cause readmission: Development and validation of a routine data-based model","authors":"Gabriela Schmid-Mohler ,&nbsp;Tobias Spiller ,&nbsp;Tudor Jumuga ,&nbsp;Ulrike Held ,&nbsp;Annina Cincera ,&nbsp;Heidi Petry ,&nbsp;Jutta Ernst ,&nbsp;Matthias Hermann","doi":"10.1016/j.ahjo.2025.100615","DOIUrl":"10.1016/j.ahjo.2025.100615","url":null,"abstract":"<div><h3>Background</h3><div>Rehospitalisation rates in patients with cardiovascular diseases are high. Routine data — including nursing data — might help identify patients at risk.</div></div><div><h3>Objective</h3><div>To evaluate the potential predictive value of routinely collected inpatient data and nursing assessment (ePA–AC) scores to identify cardiovascular inpatients at risk of unplanned 30- and 180-day all-cause rehospitalisation.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients hospitalised ≥48 h in the cardiology department from December 2012 – June 2022. The sample was divided into derivation and validation sets based on time of first hospitalisation. Logistic regression and multiple Cox proportional hazards regression analyses were applied.</div></div><div><h3>Results</h3><div>The derivation dataset included 6049 patients, the validation set 1005. Of these 7054 patients, 505 (7.2 %) experienced unplanned all-cause rehospitalisation within 30 days and 1186 (16.81 %) within 180 days post-discharge. The ROC's area under the curve (AUC) values for the 30-day logistic regression model and 180-day Cox regression model were respectively 0.61 and 0.65. Both models identified two key risk factors: ≥1 emergency department visit in the past year (OR 1.49, 95 % CI 1.18–1.86, HR 1.74, 95 % CI 1.52–2.00); and use of coumarin (OR 1.47, 95 %-CI 1.12–1.90, HR 1.27, 95 % CI 1.08–1.50). From the ePA–AC, chronic pain (HR 1.48, 95 %-CI 1.14–1.91) and acute breathing problems (HR 1.41, 95 %-CI 1.03–1.94) were risk factors for 180-day but not 30-day rehospitalisation.</div></div><div><h3>Conclusion</h3><div>Both models demonstrated low to moderate predictive value. From the ePA–AC variables, only pain and breathing problems were predictive for unplanned all-cause 180-day rehospitalisations.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"59 ","pages":"Article 100615"},"PeriodicalIF":1.8,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}